AC Immune SA vs Ensysce Biosciences
Ensysce Biosciences is the larger business, with $5.1m of revenue in fiscal 2025 against $4.3m for AC Immune SA (1.2 times as much). Ensysce Biosciences grew faster (-2.8% against -86.1%). Ensysce Biosciences kept more of each dollar of sales as profit: a net margin of -200.8% against -1971.6%. AC Immune SA carries less debt relative to equity (0.0% against 9.5%).
| Latest fiscal year | AC Immune SAACIU, 2025 | Ensysce BiosciencesENSC, 2025 |
|---|---|---|
| Revenue | $4.3m | $5.1m |
| Revenue growth | -86.1% | -2.8% |
| Net income | −$85.0m | −$10.2m |
| Operating margin | -1940.1% | -202.1% |
| Net margin | -1971.6% | -200.8% |
| Return on equity | -94.3% | — |
| Free cash flow | −$84.7m | −$7.9m |
| Cash | $33.8m | $4.3m |
| Total debt | $0 | $306,708 |
| Debt to equity | 0.0% | 9.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $213m | $5.9m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 2 sales | 2 buys, 0 sales |